 Paula Araya
Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Down Syndrome | 10 | 2025 | 455 | 2.030 |
Why?
| | Motor Skills Disorders | 1 | 2025 | 26 | 0.940 |
Why?
| | Motor Skills | 1 | 2025 | 90 | 0.890 |
Why?
| | Autistic Disorder | 1 | 2025 | 184 | 0.800 |
Why?
| | Child Development | 1 | 2025 | 452 | 0.680 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 413 | 0.560 |
Why?
| | Autoimmunity | 3 | 2024 | 869 | 0.510 |
Why?
| | Interferon-alpha | 3 | 2020 | 191 | 0.340 |
Why?
| | Proteome | 3 | 2024 | 426 | 0.320 |
Why?
| | Transcriptome | 4 | 2024 | 872 | 0.320 |
Why?
| | Melanoma, Experimental | 3 | 2019 | 105 | 0.320 |
Why?
| | Interferons | 4 | 2023 | 187 | 0.310 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 203 | 0.300 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2023 | 832 | 0.290 |
Why?
| | Dendritic Cells | 2 | 2019 | 479 | 0.250 |
Why?
| | New Zealand | 1 | 2025 | 46 | 0.240 |
Why?
| | Janus Kinase Inhibitors | 1 | 2024 | 26 | 0.230 |
Why?
| | Erythropoiesis | 1 | 2024 | 50 | 0.230 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2024 | 39 | 0.230 |
Why?
| | Heme | 1 | 2024 | 77 | 0.220 |
Why?
| | Piperidines | 1 | 2024 | 186 | 0.210 |
Why?
| | Diabetic Neuropathies | 1 | 2023 | 87 | 0.200 |
Why?
| | Growth Disorders | 1 | 2022 | 79 | 0.200 |
Why?
| | Developmental Disabilities | 1 | 2025 | 255 | 0.190 |
Why?
| | Toll-Like Receptor 3 | 2 | 2019 | 28 | 0.190 |
Why?
| | Blood | 1 | 2022 | 99 | 0.190 |
Why?
| | Pyrimidines | 1 | 2024 | 444 | 0.180 |
Why?
| | Case-Control Studies | 4 | 2023 | 3363 | 0.180 |
Why?
| | Interferon Regulatory Factors | 1 | 2021 | 33 | 0.180 |
Why?
| | Janus Kinase 1 | 1 | 2020 | 24 | 0.180 |
Why?
| | Seroconversion | 1 | 2021 | 46 | 0.180 |
Why?
| | Janus Kinase 2 | 1 | 2020 | 32 | 0.180 |
Why?
| | Azetidines | 1 | 2020 | 40 | 0.180 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 308 | 0.170 |
Why?
| | Poly A-U | 2 | 2019 | 4 | 0.170 |
Why?
| | Databases, Genetic | 1 | 2021 | 226 | 0.170 |
Why?
| | Gene Expression Profiling | 3 | 2024 | 1696 | 0.170 |
Why?
| | Photochemotherapy | 1 | 2019 | 28 | 0.170 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2019 | 380 | 0.160 |
Why?
| | Integrin alpha Chains | 1 | 2019 | 22 | 0.160 |
Why?
| | Interferon Type I | 1 | 2019 | 139 | 0.150 |
Why?
| | Metabolome | 1 | 2021 | 316 | 0.150 |
Why?
| | Neoplasms, Experimental | 1 | 2019 | 168 | 0.150 |
Why?
| | Receptors, Estrogen | 1 | 2021 | 423 | 0.150 |
Why?
| | Child, Preschool | 4 | 2025 | 10565 | 0.150 |
Why?
| | Cellular Senescence | 1 | 2019 | 176 | 0.150 |
Why?
| | Cell Lineage | 1 | 2019 | 333 | 0.140 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2670 | 0.140 |
Why?
| | Signal Transduction | 4 | 2024 | 4863 | 0.140 |
Why?
| | Hypoxia | 1 | 2024 | 1073 | 0.140 |
Why?
| | Biomarkers | 3 | 2023 | 3893 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2020 | 277 | 0.140 |
Why?
| | Sulfonamides | 1 | 2020 | 494 | 0.140 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2017 | 98 | 0.130 |
Why?
| | Antigens, CD | 1 | 2019 | 479 | 0.130 |
Why?
| | Humans | 16 | 2025 | 129705 | 0.130 |
Why?
| | Heart Defects, Congenital | 1 | 2023 | 754 | 0.130 |
Why?
| | Interferon-gamma | 1 | 2019 | 765 | 0.130 |
Why?
| | Interferon-beta | 1 | 2016 | 88 | 0.120 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 1095 | 0.120 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 293 | 0.120 |
Why?
| | Female | 10 | 2025 | 68561 | 0.120 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 592 | 0.120 |
Why?
| | Down-Regulation | 1 | 2017 | 637 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 870 | 0.120 |
Why?
| | Infant | 2 | 2025 | 9097 | 0.110 |
Why?
| | Male | 8 | 2025 | 63544 | 0.110 |
Why?
| | Adult | 7 | 2025 | 35595 | 0.100 |
Why?
| | Cell Differentiation | 1 | 2019 | 1858 | 0.100 |
Why?
| | Immunotherapy | 1 | 2016 | 581 | 0.090 |
Why?
| | Datasets as Topic | 2 | 2022 | 108 | 0.090 |
Why?
| | Young Adult | 3 | 2024 | 12363 | 0.090 |
Why?
| | Mice | 6 | 2024 | 16585 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2424 | 0.080 |
Why?
| | Animals | 8 | 2025 | 34733 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2021 | 2112 | 0.080 |
Why?
| | Proteomics | 2 | 2023 | 988 | 0.060 |
Why?
| | Adolescent | 4 | 2024 | 20355 | 0.060 |
Why?
| | Child | 4 | 2025 | 20963 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2020 | 5279 | 0.060 |
Why?
| | Pyrroles | 1 | 2024 | 201 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2023 | 27 | 0.050 |
Why?
| | Erythropoietin | 1 | 2024 | 89 | 0.050 |
Why?
| | L-Selectin | 1 | 2023 | 24 | 0.050 |
Why?
| | Receptors, Interferon | 1 | 2023 | 48 | 0.050 |
Why?
| | Perforin | 1 | 2023 | 19 | 0.050 |
Why?
| | Neurofilament Proteins | 1 | 2023 | 45 | 0.050 |
Why?
| | Cell Line, Tumor | 2 | 2021 | 3106 | 0.050 |
Why?
| | Patient Acuity | 1 | 2023 | 47 | 0.050 |
Why?
| | Stress, Physiological | 1 | 2024 | 413 | 0.050 |
Why?
| | Hypoalbuminemia | 1 | 2021 | 29 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2019 | 2778 | 0.050 |
Why?
| | Access to Information | 1 | 2021 | 48 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2021 | 157 | 0.040 |
Why?
| | Data Mining | 1 | 2021 | 109 | 0.040 |
Why?
| | Protoporphyrins | 1 | 2019 | 16 | 0.040 |
Why?
| | Hematopoiesis | 1 | 2021 | 184 | 0.040 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 182 | 0.040 |
Why?
| | Photosensitizing Agents | 1 | 2019 | 27 | 0.040 |
Why?
| | Purines | 1 | 2020 | 170 | 0.040 |
Why?
| | Biomedical Research | 1 | 2025 | 656 | 0.040 |
Why?
| | Complement Activation | 1 | 2021 | 359 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2021 | 307 | 0.040 |
Why?
| | Inpatients | 1 | 2022 | 456 | 0.040 |
Why?
| | Pyrazoles | 1 | 2020 | 403 | 0.030 |
Why?
| | Homeostasis | 1 | 2021 | 604 | 0.030 |
Why?
| | Light | 1 | 2019 | 355 | 0.030 |
Why?
| | Autoantibodies | 1 | 2024 | 1463 | 0.030 |
Why?
| | Cytokines | 1 | 2024 | 2008 | 0.030 |
Why?
| | Middle Aged | 3 | 2024 | 31103 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2023 | 1049 | 0.030 |
Why?
| | Gene Silencing | 1 | 2017 | 180 | 0.030 |
Why?
| | Metabolomics | 1 | 2021 | 592 | 0.030 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2016 | 17 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1545 | 0.030 |
Why?
| | CD11c Antigen | 1 | 2016 | 40 | 0.030 |
Why?
| | Immunologic Surveillance | 1 | 2016 | 26 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1151 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2016 | 254 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 2016 | 148 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3063 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2020 | 806 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2016 | 200 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2021 | 1171 | 0.030 |
Why?
| | Models, Animal | 1 | 2016 | 370 | 0.030 |
Why?
| | Mice, Nude | 1 | 2016 | 680 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2019 | 2075 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1707 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2019 | 816 | 0.030 |
Why?
| | Disease Progression | 1 | 2021 | 2612 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2016 | 1241 | 0.030 |
Why?
| | Quality of Life | 1 | 2025 | 2712 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2023 | 4016 | 0.030 |
Why?
| | Prognosis | 1 | 2021 | 3801 | 0.030 |
Why?
| | Liver | 1 | 2020 | 1848 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2091 | 0.020 |
Why?
| | Apoptosis | 1 | 2019 | 2485 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2340 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2021 | 10299 | 0.020 |
Why?
|
|
Araya's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|